REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

TORONTO--(BUSINESS WIRE)--Jul 1, 2025-

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

TORONTO--(BUSINESS WIRE)--Jun 30, 2025-

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures - Financial News Media

Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 -   Toronto - Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (“Cyb

$500M Financing Powers Cybin's Depression Drug With 71% Remission Rate to Final Testing

Major financing deal accelerates Cybin's breakthrough depression treatment showing 71% remission rate. See how this $500M agreement transforms mental health treatment.